Slingshot members are tracking this event:

Merck's (MRK) Keytruda Approved By FDA for New Indication in Metastatic Non-Small Cell Lung Cancer (NSCLC) With High PD-L1 Expression and No EGFR or ALK Mutations

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 24, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Keytruda, Fda, Metastatic Non-small Cell Lung Cancer, Nsclc, High Pd-l1 Expression, No Egfr, Alk, Mutations